hOKT3gamma1 (Ala-Ala) for the Prevention of Human Islet Allograft Failure
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The broad, long-term goal of this proposal is to improve the results and applicability of
islet allotransplantation early in the course of type 1 diabetes through the administration
of selective and short-term immunotherapy. More specifically, the objectives of these studies
is to conduct an open-labeled, one-year follow-up Phase I/II study in patients with surgical
and type 1 diabetes to determine the safety, tolerability, immune activity, and
pharmacokinetics of hOKT3gamma1 (Ala-ala) administration for the prevention of autoimmune
destruction and rejection of allogeneic islet transplants.